Theralase Technologies Inc. V.TLT

The 23 Optimized Patients

[Eoganacht]

I think I finally understand the data for the optimized patients. If I got anything wrong please correct me.

In the last newsletter there were 18 patients who had received an optimized treatment.

The 90 day data for those 18 patients was as follows:

44% CR (8 patients)
11% partial response (2 patients)
39% pending (7 patients)
6% no response (1 patient) 

We were waiting to find out what happened to those 7 pending patients. Would they also be CR at 90 days? Since then 5 more patients have been treated so now there are 23 patients with an optimized treatment and since there are now 3 patients pending, 2 of the 5 reached 90 days so there are 9 more patients at the 90 day mark than there were at the time of the last newsletter. Here are the results for the 23 optimized patients.

The 90 day data for the current 23 optimized patients is as follows:

52.2% CR (12 patients)
17.4% partial response (4 patients)
13 % pending (3 patients)
The news release does not explicitly tell us how many non-responders there were, but 23-19=4 therefore:
17% no response (4 patients)

Of the 9 patients who reached 90 days since the last report 
44% CR (4 patients)
22% partial response (2 patients)
33% no response (3 patients)

As the news release makes explicit there is still the potential of 82.6 CR at 90 days for the 23 optimized patients (52.2% CR + 17.4% PR + 13% pending)

[StevenBirch]

Thanks Eog, that looks good. It's too bad they can't split off the pending number.

[Pandora]

Seeing as there are only 35 or 38 patients, then for the sake of the majority of the number of investor's who are "laymen", you would think that with today's technology in spreadsheets they could make up a list for news release purposes that gives a standing for each individual patient from beginning to current status in the appropriate time windows of 90, 180, 270, 360 and 450

[enriquesuave]

Sounds very precise Eoganacht.  Of the 4 Nonresponders at 90 days, that includes 1 patient who passed away before 90 days assessment and had a high  chance of being CR given this patient had a negative urine cytology at 30 days.  Technically speaking results should be out of 22 patients, and 4 who only got a second Optimized dose should be counted separately IMo.  Results are

[jicoop]

Hey enrique , I see the tables are confusing quite a few today . I tried earlier to decipher mathematically, and welcome others to do so as well. The first table ( non optimised ) shows 25% CR Evaluated at 450 days out, which I beleive is 5 out of 20 reaching that milestone. The second table only shows 1 out of 9 hitting 450 days with a CR Evaluated of 11.1 % .  Thusly, we cannot get to the

[ScienceFirst]

EnriqueSuave ... Great support to Eoganacht's post. __________________________ enriquesuave (898) User Actions   39 minutes ago 88 Reads Post# 34577496 RE:The 23 Optimized Patients Sounds very precise Eoganacht.  Of the 4 Nonresponders at 90 days, that includes 1 patient who passed away before 90 days assessment and had

[Rumpl3StiltSkin]

Also, there is a possibility of some of the 'pending' and 'partial response' patients to achieve CR later after the 180day maintenace treatment, right? So these numbers, which are pretty great, could, in reality, improve.

[Legit62]

Great explanation, with those pending what time frame are we looking at to get final results on them? any idea when those results will show?

[langosta]

Eoganacht, do you think you would be interested in a part time job creating News Reports for Theralase?  :-)

[ScienceFirst]

Eoganacht ... Great analysis.  Thanks for sharing. __________________________ Eoganacht (2057) 49 minutes ago 169 Reads Post# 34577447 The 23 Optimized Patients I think I finally understand the data for the optimized patients. If I got anything wrong please correct me. In the last newsletter there were 18 patients who had received an

[MineDigger]

Eog, thanks for that "dissection" of the data, so any chance you also "dissect" this highlighted part of this sentence for me "The Study II optimized treatment patients, who received either an optimized primary study treatment or optimized maintenance study treatment consisted of: 23 patients at 90 days, 26 patients at 180 days and 27 patients at each of 270, 360 and

[stocksnbonds458]

For me, the only relevant data is the 23 optimized patients in phase two- these are the ONLY numbers I have been waiting for. After 90 days 52.2% of these 23 patients is CR according to TLT. This as an ABSOLUTELY ASTOUNDING number. For them to say encouraging instead of doing backflips and shouting from the building tops is because they are playing it low key for obvious reasons. This is game

[Rumpl3StiltSkin]

and at 180 days this same group will all get a second optiized treatment. I'm guessing this number could be close to the final number of CR at 450 days. We're talking about mostly an older and fragile patient population here. Could be a bunch of reasons why they aren't CR after 90 days... And I expect as we get more optimized patients treated this 90day CR % will improve a bit as well

[Eoganacht]

Hi MineDigger. I don't understand that part of the news release either.

[socksnblonds642]

Think it means that new patients came on board during the study no? Days since the trial started maybe instead days from first dose. I think someone effed up the dates.  That's not an important sentence anyhow IMO. The chart tells all. The efficacy is up large with little or maybe no health risk per the data. 

[Rumpl3StiltSkin]

I think any time a company releases data where lots of numbers are involved, it is a risk. I will say that this time they did an overall better job. However, I also don't think that part in red below is correct, is what they wanted to state...